Down-regulated MicroRNAs in Gastric Carcinoma May Be Targets for Therapeutic Intervention and Replacement Therapy

Ulrich H Weidle1, Fabian Birzele2, Simon Auslaender1

  • 1Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.

Anticancer Research
|September 3, 2021
PubMed

Insights

Gastric cancer remains a significant global health challenge. This study identifies specific microRNAs, including miR-133b/a and miR-518, as promising therapeutic targets for treating this intractable disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gastric cancer is a leading cause of cancer death globally, with high recurrence and metastatic disease rates.
  • Current treatments face challenges due to disease intractability and recurrence.
  • Novel therapeutic targets and treatment modalities are urgently needed for gastric cancer.

Purpose of the Study:

  • To identify microRNAs (miRNAs) that are downregulated in gastric cancer and demonstrate efficacy in preclinical models.
  • To evaluate the potential of these miRNAs as therapeutic targets for gastric cancer treatment.

Main Methods:

  • Literature search for downregulated miRNAs in gastric cancer with demonstrated efficacy in xenograft models.
  • Analysis of miRNA targets, focusing on transcription factors, cell cycle, apoptosis, and GTPase-related pathways.
  • Evaluation of miRNAs based on prognostic impact, functional data, and tractability.

Main Results:

  • Identified 25 miRNAs targeting transcription factors, including seven regulating cell-cycle and apoptosis, and five regulating GTPase-related targets.
  • miR-133b/a (targeting MCL1) and miR-518 (targeting MDM2) were among the identified miRNAs.
  • These specific miRNAs showed potential based on prognostic impact and functional data.

Conclusions:

  • miR-133b/a and miR-518 are suggested as potentially valuable targets for further investigation in gastric cancer.
  • Reconstitution therapy with specific miRNAs may offer a novel treatment strategy for gastric cancer.
  • Further evaluation is warranted to explore the therapeutic potential of these miRNAs in gastric cancer treatment.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K